Gilead Sciences (GILD) Was Upgraded by Jefferies to Buy; Energen (EGN) Sellers Increased By 2.29% Their Shorts

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 19 have Buy rating, 0 Sell and 11 Hold. Therefore 63% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.04’s average target is 19.52% above currents $81.19 stock price. Gilead Sciences had 112 analyst reports since July 29, 2015 according to SRatingsIntel. The stock has “Hold” rating by Argus Research on Friday, July 29. Maxim Group maintained the stock with “Hold” rating in Thursday, July 27 report. On Monday, August 28 the stock rating was maintained by BMO Capital Markets with “Hold”. On Wednesday, July 29 the stock rating was maintained by RBC Capital Markets with “Outperform”. The company was maintained on Wednesday, July 29 by Needham. J.P. Morgan maintained it with “Buy” rating and $8000 target in Monday, July 24 report. On Monday, August 28 the stock rating was maintained by Maxim Group with “Hold”. The firm has “Hold” rating given on Wednesday, September 9 by Jefferies. The firm earned “Outperform” rating on Tuesday, January 16 by Wells Fargo. The company was upgraded on Thursday, August 31 by Argus Research.

Energen Corporation (NYSE:EGN) had an increase of 2.29% in short interest. EGN’s SI was 3.25 million shares in January as released by FINRA. Its up 2.29% from 3.17 million shares previously. With 659,700 avg volume, 5 days are for Energen Corporation (NYSE:EGN)’s short sellers to cover EGN’s short positions. The SI to Energen Corporation’s float is 3.36%. The stock decreased 4.23% or $2.45 during the last trading session, reaching $55.52. About 1.14 million shares traded or 33.84% up from the average. Energen Corporation (NYSE:EGN) has risen 35.21% since January 26, 2017 and is uptrending. It has outperformed by 18.51% the S&P500.

Among 38 analysts covering Energen Corporation (NYSE:EGN), 25 have Buy rating, 2 Sell and 11 Hold. Therefore 66% are positive. Energen Corporation had 113 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets with “Hold” on Thursday, September 14. The stock of Energen Corporation (NYSE:EGN) earned “Accumulate” rating by Johnson Rice on Tuesday, February 16. The rating was maintained by BMO Capital Markets on Thursday, March 23 with “Hold”. The firm has “Hold” rating by RBC Capital Markets given on Thursday, July 6. The rating was maintained by BMO Capital Markets on Thursday, August 10 with “Hold”. As per Thursday, October 5, the company rating was maintained by Stifel Nicolaus. Nomura maintained it with “Buy” rating and $65 target in Thursday, October 13 report. Suntrust Robinson maintained the shares of EGN in report on Tuesday, February 16 with “Buy” rating. iBERIA Capital Partners maintained Energen Corporation (NYSE:EGN) rating on Tuesday, March 22. iBERIA Capital Partners has “Outperform” rating and $41 target. On Tuesday, August 16 the stock rating was maintained by Barclays Capital with “Equal-Weight”.

Investors sentiment decreased to 1.02 in 2017 Q3. Its down 0.19, from 1.21 in 2017Q2. It fall, as 34 investors sold Energen Corporation shares while 86 reduced holdings. 41 funds opened positions while 81 raised stakes. 89.38 million shares or 7.87% less from 97.02 million shares in 2017Q2 were reported. Virginia Retirement Sys Et Al invested 0.02% in Energen Corporation (NYSE:EGN). The Manitoba – Canada-based Great West Life Assurance Can has invested 0.01% in Energen Corporation (NYSE:EGN). 28,432 were accumulated by Citadel Advsr Lc. Gruss And owns 15,100 shares. Services Corporation, a Missouri-based fund reported 24 shares. Millennium Management Ltd Limited Liability Company has 0.13% invested in Energen Corporation (NYSE:EGN). Regions Fincl has invested 0.01% in Energen Corporation (NYSE:EGN). Federated Invsts Pa stated it has 45,680 shares. Marshall Wace Limited Liability Partnership reported 0.01% of its portfolio in Energen Corporation (NYSE:EGN). State Of Tennessee Treasury Department has invested 0.02% in Energen Corporation (NYSE:EGN). Alliancebernstein L P holds 0% of its portfolio in Energen Corporation (NYSE:EGN) for 55,455 shares. Ameriprise Financial reported 441,412 shares. Voya Investment Management Limited Com accumulated 0% or 27,200 shares. Hong Kong-based Point72 Asia (Hong Kong) Ltd has invested 0% in Energen Corporation (NYSE:EGN). Putnam Investments Ltd Liability Co has invested 0.01% in Energen Corporation (NYSE:EGN).

Energen Corporation, through its subsidiary, Energen Resources Corporation, engages in the exploration, development, and production of oil, natural gas liquids, and natural gas. The company has market cap of $5.40 billion. It has activities within the Midland Basin, the Delaware Basin, and the Central Basin Platform areas of the Permian Basin in west Texas and New Mexico. It currently has negative earnings.

Since August 1, 2017, it had 0 insider buys, and 13 selling transactions for $51.52 million activity. $5.56 million worth of stock was sold by MARTIN JOHN C on Tuesday, August 1. 60,000 shares were sold by Meyers James R, worth $4.99 million on Thursday, August 31. On Friday, September 1 Alton Gregg H sold $2.08 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) or 25,000 shares. Washington Robin L had sold 51,820 shares worth $4.40 million on Thursday, September 7.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 earnings per share, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18 billion for 12.15 P/E if the $1.67 EPS becomes a reality. After $2.23 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $106.06 billion. The companyÂ’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 9.24 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

The stock decreased 0.14% or $0.11 during the last trading session, reaching $81.19. About 4.71 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 26, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Investors sentiment increased to 1.03 in Q3 2017. Its up 0.10, from 0.93 in 2017Q2. It is positive, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Holowesko holds 1.22 million shares or 7.86% of its portfolio. Denver Invest Advisors has 0.03% invested in Gilead Sciences, Inc. (NASDAQ:GILD) for 6,552 shares. Chilton Cap Mngmt Ltd Co, Texas-based fund reported 16,205 shares. 232,002 are held by Comml Bank Of Nova Scotia. Edgewood Mngmt Limited Co has invested 0.08% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). Kentucky Retirement stated it has 0.49% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD). 12,093 were reported by Counselors. Brown Brothers Harriman And holds 308 shares. Deutsche State Bank Ag holds 0.6% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 10.84M shares. Puzo Michael J owns 15,846 shares or 0.67% of their US portfolio. Beech Hill Advisors invested in 0.45% or 10,475 shares. Hyman Charles D holds 0.03% or 3,064 shares in its portfolio. Wellington Llp, a Massachusetts-based fund reported 1.54M shares. 26,999 were reported by Girard Limited. Rnc Capital Mngmt Ltd Company owns 11,471 shares or 0.07% of their US portfolio.